<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907877</url>
  </required_header>
  <id_info>
    <org_study_id>MS-Resp-CoV-2-A0003</org_study_id>
    <nct_id>NCT04907877</nct_id>
  </id_info>
  <brief_title>Bifido- and Lactobacilli in Symptomatic Adult COVID-19 Outpatients</brief_title>
  <acronym>ProCOVID</acronym>
  <official_title>Role of Nutritional Support With Probiotics in Adult Outpatients With Symptomatic COVID-19: a Randomized Dietary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Biotic Sp. z o.o.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Biotic Sp. z o.o.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is evidence that some types of probiotics play a role in alleviation of symptoms of&#xD;
      acute respiratory tract infections and bursting immune response to respiratory and enteric&#xD;
      viruses. Available data serves a rationale for the study exploring a role of nutritional&#xD;
      support with probiotics in adult outpatients with COVID-19. Hypothesis of the study is that a&#xD;
      proposed mixture of lactobacilli and bifidobacteria facilitate faster recovery from COVID-19&#xD;
      and enhance specific immune response to SARS-CoV-2 antigens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three hundred healthy adults, permanently residing and contacting (a contact subject) with a&#xD;
      household patient with confirmed COVID-19 (primary patient), or who stayed in close long&#xD;
      protected contact with a person who consequently become SARS-CoV-2 positive, will be screened&#xD;
      for the study. When the contact subject meets enrollment criteria, he/she will be randomized&#xD;
      to take an investigational product (probiotic, test dietary supplement, TDS), a mixture of&#xD;
      lactobacilli and bifidobacteria or placebo 1 time a day before breakfast. During screening&#xD;
      period, he/she will also keep Screening and Compliance Diary for screening of COVID-19&#xD;
      symptoms and confirming TDS intake.&#xD;
&#xD;
      Duration of the screening period (Days 0-X) will depend on the health status of a contact&#xD;
      person. If the contact remains asymptomatic, duration of probiotic intake will be 30 days.&#xD;
      After this period, subject will be excluded from the study .&#xD;
&#xD;
      If the contact develops symptoms, he/she will call family physician, request a referral, and&#xD;
      visit a local center to make PCR test of the nasal swab for SARS-CoV-2. While result of PCR&#xD;
      test are being available (Days 0-2), the patient will continue taking TDS and start keeping&#xD;
      Respiratory Illness Diary. If the result of the PCR test is negative the patient will be&#xD;
      withdrawn from the study. If the result is positive, he/she will continue participation and&#xD;
      be visited by the nurse (Nurse Visit 1, Days 3-5), who supplies the patient with TDS in&#xD;
      amount enough to complete 28-day intake period and takes blood for anti-SARS-CoV-2 IgG.&#xD;
&#xD;
      During 28-day period of TDS intake, the patient will keep Respiratory Illness Diary (the&#xD;
      Diary is designed for evaluation of the COVID-19 course and assessment of TDS reduces&#xD;
      clinical manifestation of COVID-19), the investigator/family physician updated with health&#xD;
      status, and the physician will make weekly phone calls to assess patient health status,&#xD;
      indications for hospitalization, treatment, checking TDS intake and Respiratory Illness&#xD;
      Diary. In the case of patient hospitalization, patient is withdrawn from the study, and will&#xD;
      be requested to provide a reference from Medical Records after hospital discharge.&#xD;
&#xD;
      During Nurse Visit 2 (Days 28-35), after finishing TDS intake, the nurse will collect&#xD;
      Respiratory Illness Diary, empty vials with TDS, take blood for anti-SARS-CoV-2 IgG test. The&#xD;
      test is necessary to evaluate if TDS intake improves post-COVID-19 immunity on short-term&#xD;
      perspective. At the end of the 2nd visit, the nurse will give enveloped Post-COVID-19&#xD;
      Questionnaire to be completed in 3 months.&#xD;
&#xD;
      In 3 months, investigator/family physician will call to the patient and remind to return a&#xD;
      completed Post-COVID-19 Questionnaire. Post-COVID-19 Questionnaire will help to see if active&#xD;
      TDS reduces presentation of Post-COVID-19 syndrome.&#xD;
&#xD;
      In 6 months, the study nurse will perform Nurse Visit 3 and draw blood for the&#xD;
      anti-SARS-CoV-2 IgG. The test is necessary to evaluate if TDS intake improves post-COVID-19&#xD;
      immunity on long term perspective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global symptom score</measure>
    <time_frame>10 days</time_frame>
    <description>Clinical score of Coronavirus disease-19; minimal score 0 (healthy), maximal score 36 (worst disease)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>8 - point ordinal severity scale of coronavirus disease-19</measure>
    <time_frame>28 days</time_frame>
    <description>World Health Organization scale; score 0 - healthy, score 8 - death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>28 days</time_frame>
    <description>Day when patient symptom score is 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of completely recovered patients</measure>
    <time_frame>28 days</time_frame>
    <description>Patients with symptom score is 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization rate</measure>
    <time_frame>28 days</time_frame>
    <description>Percent hospitalized due to COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of symptomatic infection</measure>
    <time_frame>30 days</time_frame>
    <description>Percent of symptomatic infections in active and placebo groups</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-SARS-CoV-2 antibodies IgG response</measure>
    <time_frame>Days 3-5, day 28-35, month 6th</time_frame>
    <description>Antibody titer to NCP and spike antigen</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19 Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NordBiotic ImmunoVir, a mixute of bidido- and lactobacteria administered in a dose of 5 billion once a day for X-30 plus 28 days of the disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrine administered once a day for X-30 plus 28 days of the disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietary Supplement</intervention_name>
    <description>Probiotic/Placebo will be taken 1 time a day before breakfast for 30 days. In the case of the secondary disease, it will be continued for 28 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 - ≤ 65 years;&#xD;
&#xD;
          2. Male or non-pregnant female;&#xD;
&#xD;
          3. Informed virtual pre-consent and paper signed consent forms;&#xD;
&#xD;
          4. Absence of COVID-19 symptoms at time of screening;&#xD;
&#xD;
          5. Symptomatic household with confirmed COVID-19 infection;&#xD;
&#xD;
          6. Sharing the same premise/flat with a COVID-19 patient at least 8 hours per day;&#xD;
&#xD;
          7. Unprotected (without mask) close contact lasting more than 4 hours with a coughing&#xD;
             person who has been further confirmed COVID-19&#xD;
&#xD;
          8. The duration of contact with the first patient with COVID-19 is less than 14 days&#xD;
&#xD;
          9. Subject understands and agrees to comply with study procedures including triple blood&#xD;
             analysis for anti-SARS-CoV-2 IgG in the case of the disease;&#xD;
&#xD;
         10. Subject has a smartphone and can make photocopies of documents using a smartphone and&#xD;
             send them via messengers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. COVID-like symptoms in the previous 6 months ;&#xD;
&#xD;
          2. Vaccination against SARS-CoV-2 in the previous 12 months;&#xD;
&#xD;
          3. Risk for the complicated course of COVID-19 due to:&#xD;
&#xD;
             3.1. Hypertension; 3.2. Diabetes mellitus; 3.3. Immunosuppressive conditions; 3.4.&#xD;
             Chronic pathology of the respiratory system ; 3.5. Chronic pathology of the&#xD;
             cardiovascular system ; 3.6. Malignant tumor ; 3.7. Systemic inflammatory connective&#xD;
             tissue disease ; 3.8. Cerebrovascular disease ; 3.9. Chronic hepatitis. Hepatic&#xD;
             cirrhosis; 3.10. Inflammatory bowel diseases ; 3.11. Chronic kidney disease ;&#xD;
&#xD;
          4. Drug or alcohol abuse as suspected by investigator;&#xD;
&#xD;
          5. History of persistent diarrhea of any cause;&#xD;
&#xD;
          6. Use of pre- or probiotics during the last 2 weeks before inclusion or current use;&#xD;
&#xD;
          7. Allergy to any components of the TDS;&#xD;
&#xD;
          8. Technical difficulties to perform virtual study visits.&#xD;
&#xD;
          9. Inability to perform a blood test for antibodies after 6 months&#xD;
&#xD;
         10. Inability to swallow capsules, or choking / coughing while eating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zoriana Hoda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lviv State Laboratory Center, Ministry of Health of Ukraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sergiy V. Gerasymov, MD, PhD</last_name>
    <phone>+380679375951</phone>
    <email>mediana.statistics@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michal P Jakubowski</last_name>
    <phone>+48602702199</phone>
    <email>mj@nordicbiotic.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, Li P, Hu B, Wang J, Hu C, Jin Y, Niu X, Ping R, Du Y, Li T, Xu G, Hu Q, Tu L. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020 May;115(5):766-773. doi: 10.14309/ajg.0000000000000620.</citation>
    <PMID>32287140</PMID>
  </results_reference>
  <results_reference>
    <citation>Smyk W, Janik MK, Portincasa P, Milkiewicz P, Lammert F, Krawczyk M. COVID-19: Focus on the lungs but do not forget the gastrointestinal tract. Eur J Clin Invest. 2020 Sep;50(9):e13276. doi: 10.1111/eci.13276. Epub 2020 Jul 5. Review.</citation>
    <PMID>32406522</PMID>
  </results_reference>
  <results_reference>
    <citation>Westermann C, Gleinser M, Corr SC, Riedel CU. A Critical Evaluation of Bifidobacterial Adhesion to the Host Tissue. Front Microbiol. 2016 Aug 5;7:1220. doi: 10.3389/fmicb.2016.01220. eCollection 2016. Review.</citation>
    <PMID>27547201</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Tassell ML, Miller MJ. Lactobacillus adhesion to mucus. Nutrients. 2011 May;3(5):613-36. doi: 10.3390/nu3050613. Epub 2011 May 20. Review.</citation>
    <PMID>22254114</PMID>
  </results_reference>
  <results_reference>
    <citation>Olaimat AN, Aolymat I, Al-Holy M, Ayyash M, Abu Ghoush M, Al-Nabulsi AA, Osaili T, Apostolopoulos V, Liu SQ, Shah NP. The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. NPJ Sci Food. 2020 Oct 5;4:17. doi: 10.1038/s41538-020-00078-9. eCollection 2020. Review.</citation>
    <PMID>33083549</PMID>
  </results_reference>
  <results_reference>
    <citation>Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, Chung AC, Cheung CP, Tso EY, Fung KS, Chan V, Ling L, Joynt G, Hui DS, Chow KM, Ng SSS, Li TC, Ng RW, Yip TC, Wong GL, Chan FK, Wong CK, Chan PK, Ng SC. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021 Apr;70(4):698-706. doi: 10.1136/gutjnl-2020-323020. Epub 2021 Jan 11.</citation>
    <PMID>33431578</PMID>
  </results_reference>
  <results_reference>
    <citation>Chai W, Burwinkel M, Wang Z, Palissa C, Esch B, Twardziok S, Rieger J, Wrede P, Schmidt MF. Antiviral effects of a probiotic Enterococcus faecium strain against transmissible gastroenteritis coronavirus. Arch Virol. 2013 Apr;158(4):799-807. doi: 10.1007/s00705-012-1543-0. Epub 2012 Nov 28.</citation>
    <PMID>23188495</PMID>
  </results_reference>
  <results_reference>
    <citation>Miettinen M, Pietilä TE, Kekkonen RA, Kankainen M, Latvala S, Pirhonen J, Österlund P, Korpela R, Julkunen I. Nonpathogenic Lactobacillus rhamnosus activates the inflammasome and antiviral responses in human macrophages. Gut Microbes. 2012 Nov-Dec;3(6):510-22. doi: 10.4161/gmic.21736. Epub 2012 Aug 16.</citation>
    <PMID>22895087</PMID>
  </results_reference>
  <results_reference>
    <citation>Nakayama Y, Moriya T, Sakai F, Ikeda N, Shiozaki T, Hosoya T, Nakagawa H, Miyazaki T. Oral administration of Lactobacillus gasseri SBT2055 is effective for preventing influenza in mice. Sci Rep. 2014 Apr 10;4:4638. doi: 10.1038/srep04638.</citation>
    <PMID>24717726</PMID>
  </results_reference>
  <results_reference>
    <citation>Gao X, Huang L, Zhu L, Mou C, Hou Q, Yu Q. Inhibition of H9N2 Virus Invasion into Dendritic Cells by the S-Layer Protein from L. acidophilus ATCC 4356. Front Cell Infect Microbiol. 2016 Oct 25;6:137. eCollection 2016.</citation>
    <PMID>27826541</PMID>
  </results_reference>
  <results_reference>
    <citation>Vouloumanou EK, Makris GC, Karageorgopoulos DE, Falagas ME. Probiotics for the prevention of respiratory tract infections: a systematic review. Int J Antimicrob Agents. 2009 Sep;34(3):197.e1-10. doi: 10.1016/j.ijantimicag.2008.11.005. Epub 2009 Jan 28. Review.</citation>
    <PMID>19179052</PMID>
  </results_reference>
  <results_reference>
    <citation>Zimmermann P, Curtis N. The influence of probiotics on vaccine responses - A systematic review. Vaccine. 2018 Jan 4;36(2):207-213. doi: 10.1016/j.vaccine.2017.08.069. Epub 2017 Sep 18. Review.</citation>
    <PMID>28923425</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nordic Biotic Sp. z o.o.</investigator_affiliation>
    <investigator_full_name>Sergei Gerasymov, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not applicable as not decided yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

